Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alessa Therapeutics

Request full access

Alessa Therapeutics is a pre-clinical stage company

San Carlos, United StatesFounded 2018Biotech & Life Sciences

About Alessa Therapeutics

Alessa Therapeutics specializes in the development of localized, sustained drug delivery systems targeting prostate diseases, particularly prostate cancer and benign prostate hyperplasia. Founded by Dr. Pamela Munster and her team at UCSF's Department of Medicine, the company aims to revolutionize oncology treatments through innovative implantable therapies. Alessa's core product involves drug-eluting implants that deliver anti-androgen therapy directly to the prostate, minimizing systemic side effects and enhancing treatment efficacy. The company operates in the oncology and urology markets, serving patients with prostate conditions. Alessa's business model focuses on clinical research and development, with revenue generated through partnerships, grants, and future commercialization of its proprietary technology. Currently, the company is conducting several clinical trials, including a Phase 1 study in collaboration with the National Cancer Institute, to validate the feasibility and effectiveness of its treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
17
Open positions
None listed
Dealroom signal
72.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Dec 2024 $15M $60M Mission BioCapital · Johnson & Johnson ↗
EARLY VCEquity / VC Jan 2020 $3.3M $13M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Alessa Therapeutics website traffic

Latest recorded traffic for Alessa Therapeutics is 570 monthly website visits, down 85% over the last three months. Alessa Therapeutics's team grew 13.3% over the past year.

Latest monthly visits570 3-month web change-85% 1-year team growth+13.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alessa Therapeutics in the San Carlos ecosystem

Live from Dealroom

The Alessa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Mission BioCapital
  • Johnson & Johnson

Other known investors4 additional known investors

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alessa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alessa Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.